|1.||Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|5.||Paraproteinemias (Monoclonal Gammopathy)
|1.||Ando, Yukio: 75 articles (12/2015 - 03/2002)|
|2.||Ueda, Mitsuharu: 30 articles (03/2014 - 02/2004)|
|3.||Obayashi, Konen: 29 articles (09/2014 - 03/2002)|
|4.||Suhr, Ole B: 21 articles (12/2015 - 03/2002)|
|5.||Ando, Y: 21 articles (06/2011 - 02/2000)|
|6.||Jono, Hirofumi: 20 articles (12/2014 - 06/2009)|
|7.||Nakamura, Masaaki: 20 articles (11/2010 - 03/2002)|
|8.||Saraiva, Maria João: 18 articles (03/2015 - 11/2002)|
|9.||Saraiva, M J: 18 articles (12/2014 - 01/2000)|
|10.||Yamashita, Taro: 18 articles (12/2013 - 11/2003)|
|1.||Intravenous Immunoglobulins (IVIG)FDA Link
01/15/2014 - "These results suggest that IVIG is effective for inflammatory demyelinating polyneuropathy by inhibiting the chemotactic factor of macrophages. "
02/01/2015 - "Evidence from controlled clinical trials has established IVIg as a first-line therapy for Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. "
09/01/2005 - "There is clinical evidence, based on controlled trials, for the effectiveness of IVIG in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal neuropathy with conduction blocks. "
01/01/1993 - "Between June 1989 and February 1992, in an open controlled study 16 patients with various types of polyneuropathy were treated with high-dose intravenous immunoglobulins (IgIV). "
12/01/2014 - "Efficiency of long-term treatment with intravenous immunoglobulins correlates with reduced autoreactive T cell responses in chronic inflammatory demyelinating polyneuropathy patients."
02/01/1991 - "Of 52 patients fulfilling the criteria of chronic inflammatory demyelinating polyneuropathy, 20 (38%) did not improve after intravenous immunoglobulin treatment, two (4%) had a short-lasting improvement and subsequent infusions had no effect, nine (17%) reached a spontaneously or therapeutically induced complete remission, and 21 patients (40%) needed intermittent infusions to maintain improvement. "
10/01/1998 - "There was improvement and sustained remission in the polyneuropathy following treatment with intravenous immunoglobulin. "
01/01/2009 - "Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up."
06/01/2011 - "The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin."
10/01/1992 - "Chronic inflammatory polyneuropathy associated with nephropathy and antifactor VIII antibody: improvement with intravenous immunoglobulin."
|3.||Adrenal Cortex Hormones (Corticosteroids)IBA
09/17/1994 - "Corticosteroids are usually effective in most patients, particularly in reducing the oedema and controlling the polyneuropathy."
06/01/2008 - "Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody."
04/01/1996 - "Corticosteroids are not as effective and should be withheld except when, in protracted courses, suspicion of chronic inflammatory demyelinating polyneuropathy arises."
01/01/1996 - "A course of systemic corticosteroids was begun, but the cutaneous eruptions persisted; and in addition the patient developed signs of polyneuropathy in the lower extremities secondary to neurologic vasculitic lesions. "
11/01/1976 - "Diphasic response to corticosteroids in idiopathic relapsing polyneuropathy."
|4.||Immunoglobulin M (IgM)IBA
02/01/2005 - "In patients with IgM antibody-associated polyneuropathy, RTX improved muscle strength, and repeated treatments over 2 years were well tolerated. "
08/24/2004 - "Three patients with chronic inflammatory demyelinating polyneuropathy (30%) and one patient with IgM neuropathy (13%) improved. "
07/01/1997 - "The IgM-associated Polyneuropathy Study Group."
09/01/1995 - "IgM-associated Polyneuropathy Study Group."
08/01/1985 - "Immunofluorescence histochemistry was used to study the pathogenesis of polyneuropathy in patients with an IgM M protein. "
|5.||Prednisone (Sone)FDA LinkGeneric
01/01/1989 - "Case 1 developed four relapses of ascending sensory-motor deficit with conduction blocks suggestive of a superimposed chronic inflammatory polyneuropathy (CIP) which improved under prednisone. "
11/01/1998 - "We report 2 patients with this disorder to describe two underrecognized treatment outcomes--worsening of polyneuropathy with initiation of alpha-Ifn, in the absence of immunosuppression, and deterioration of liver function with prednisone, despite improvement of polyneuropathy."
10/01/1994 - "One patient had a MGUS-associated hypertrophic demyelinating and prednisone-dependent polyneuropathy, followed over a course of two and a half years. "
03/15/1989 - "The relapse was treated with pulse doses of prednisone alone with complete resolution of his polyneuropathy and skin changes. "
01/01/1983 - "A chronic relapsing polyneuropathy did not improve with oral prednisone therapy. "
|6.||Immunoglobulin G (IgG)IBA
10/01/2015 - "Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy."
08/01/2013 - "Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?"
12/01/2003 - "I propose that a) there is a higher incidence of Chronic Immune Dysschwannian/Dysneuronal Polyneuropathy-like neuropathy in type-2 diabetes patients and in patients with a strong family history of type-2 diabetes, and b) the intravenous immunoglobulin-G-treatable neuropathy in type-2 diabetes can be brought on by the genetico-diabetoid-2 state. "
12/01/2003 - "The intravenous immunoglobulin-G responsive type-2 diabetes polyneuropathy usually is dysschwannian, sometimes mainly dysneuronal intravenous immunoglobulin-G, the most beneficial and safest treatment, is costly, but if intravenous immunoglobulin-G-treatability of a dysimmune component of type-2 diabetes neuropathy is overlooked, dismissed or rejected, as commonly happens, other costs are high regarding the patient's worsening morbidity and disability, and resultant need for increased medical care. "
01/01/2002 - "High anti-GM1 and anti-GD1a IgG antibody titers are detected in Guillain-Barré syndrome but not in chronic inflammatory demyelinating polyneuropathy."
|7.||rituximab (Mabthera)FDA Link
10/01/2007 - "Rituximab can be effective in anti-MAG polyneuropathy but can possibly lead to unexpected consequences in individuals with MS."
03/01/2009 - "Report a double-blind, placebo-controlled study of rituximab in patients with anti-MAG demyelinating polyneuropathy (A-MAG-DP). "
08/15/2013 - "NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy."
09/01/2012 - "Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy."
05/01/2012 - "Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy."
|8.||Lidocaine (Xylocaine)FDA LinkGeneric
09/01/2005 - "The lidocaine patch 5% appeared well tolerated and potentially effective in the management of painful idiopathic distal sensory polyneuropathy. "
09/01/2005 - "We have therefore conducted a safety, tolerability, and effectiveness study of the lidocaine patch 5% in painful idiopathic distal sensory polyneuropathy. "
09/01/2005 - "An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy."
08/20/1999 - "Treatment of painful distal sensory polyneuropathy in HIV-infected patients with a topical agent: results of an open-label trial of 5% lidocaine gel."
01/01/2006 - "Thus, distal-leg skin biopsy, QST, and sensory NCS cannot be used to identify patients with painful polyneuropathy likely to respond to a lidocaine patch in clinical practice. "
|9.||Melphalan (Alkeran)FDA LinkGeneric
11/01/2011 - "Similar clinical recovery was seen in primary systemic AL amyloidosis patients with polyneuropathy after high dose melphalan with auto-PBSCT. "
10/01/2011 - "However, High-dose melphalan with ASCT should be considered carefully due to its treatment-related morbidity (Vuckovic et al., Blood 2003;101:2314-2317), especially in patients with poor performance status owing to polyneuropathy and multiorgan involvement, such as cardiac, respiratory, and renal failure. "
01/01/2009 - "We report a case of light chain deposition disease associated with plasma cell dyscrasia presenting as sicca syndrome with salivary glands hypertrophy and polyneuropathy successfully treated by high dose melphalan and autologous blood stem transplantation. "
02/01/1984 - "A patient with a severe remote-effect polyneuropathy and other paraneoplastic features of osteosclerotic myeloma improved dramatically with melphalan and prednisone treatment. "
05/01/1987 - "A patient with a severe polyneuropathy in association with osteosclerotic myeloma improved after melphalan and prednisone treatment. "
04/21/2000 - "Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M."
08/01/1986 - "We also analysed prealbumin mRNAs in the livers of a disease-free individual and one with familial amyloidotic polyneuropathy and confirmed that there is no difference in the levels and sizes of the prealbumin mRNAs between the two. "
01/01/2010 - "The authors reviewed contribution of Kumamoto University group to the progress of the studies on transthyretin (TTR)-related familial amyloidotic polyneuropathy (TTR-related FAP) for 42 years (from 1967 to 2009). "
10/01/2003 - "Transthyretin familial amyloidotic polyneuropathy: histopathological study of the explanted livers."
09/01/1998 - "To study the alterations in the structure and innervation of eccrine glands in familial amyloidotic polyneuropathy (FAP) type I with Val 30 Met transthyretin mutation. "
01/01/1997 - "Severe polyneuropathy in a 3-year-old child after dichlorophenoxyacetic herbicide--chwastox intoxication, treated successfully with plasmapheresis (PF)."
01/01/1990 - "Long-term plasmapheresis therapy is effective and safe in children with chronic relapsing dysimmune polyneuropathy."
01/01/1993 - "Despite an initial response to plasmapheresis, the patient's polyneuropathy deteriorated and subsequently improved with corticosteroid therapy. "
08/01/1986 - "For patients with chronic inflammatory polyneuropathy, plasmapheresis has produced clinical improvement in 50% of corticosteroid-refractory patients. "
05/01/1986 - "A short course of plasmapheresis improved the bleeding time but did not alter the polyneuropathy."
|2.||Drug Therapy (Chemotherapy)
08/01/1997 - "Marked improvement of severe polyneuropathy associated with multifocal osteosclerotic myeloma following surgery, radiation, and chemotherapy."
01/01/2004 - "To assess whether drug therapy for chronic idiopathic axonal polyneuropathy reduces disability, ameliorates neurological symptoms and associated impairments, and whether treatment is safe. "
04/01/1999 - "Lymph node swelling and polyneuropathy improved in some degree after chemotherapy. "
01/01/2014 - "The animal models in this study can be used to elucidate pathomechanisms underlying chemotherapy-induced polyneuropathy and for the development of novel therapeutic and preventative strategies. "
01/01/2004 - "We sought all randomised or quasi-randomised (alternate or other systematic treatment allocation), unconfounded trials that examined the effects of any drug therapy in patients with chronic idiopathic axonal polyneuropathy at least one year after the onset of treatment. "
10/01/1996 - "Liver transplantation is the only effective treatment of familial amyloidotic polyneuropathy type I (FAP). "
01/01/1998 - "Liver transplantation is a new treatment for familial amyloidotic polyneuropathy (FAP). "
04/01/2008 - "The objective of the present study was to analyze hepatic mitochondrial function in patients with familial amyloidotic polyneuropathy (FAP) undergoing cadaveric donor orthotopic liver transplantation. "
09/15/2000 - "The aim of this study was to investigate familial amyloidotic polyneuropathy, Portuguese type patients' endocrine cell content in the stomach and duodenum before and after liver transplantation, and to relate the findings to the patients' gastrointestinal disturbances. "
01/01/2000 - "Orthotopic liver transplantation for familial amyloidotic polyneuropathy: a pathological study."
04/01/1997 - "The potential for complete response to plasma exchange should be recognized in patients with symptoms, signs, and nerve conduction studies suggestive of chronic inflammatory demyelinating polyneuropathy."
02/01/1983 - "The clinical features, results of nerve conduction studies and sural nerve biopsy findings have been compared in 5 patients with chronic relapsing polyneuropathy in whom plasma exchange was used in treatment. "
01/01/2004 - "Four patients with demyelinating polyneuropathy underwent outpatient plasma exchange of 1-1 1/4 plasma volumes using Bard CathLink 20 venous access devices for up to 2 1/2 years. "
01/01/2002 - "Six patients with paraproteinemic polyneuropathies underwent 64 outpatient plasma exchanges using the CathLink 20 for access, 31 using 2 CathLink 20's (draw and return), 20 using a single CathLink 20 as the draw site and 13 using a single CathLink 20 as the return site. "
08/01/1996 - "Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. "
08/27/1997 - "In conclusion, our results suggest that liver transplant may be useful in the treatment of certain cases of familial amyloidotic polyneuropathy to stop the neurological deterioration of the patients and to avoid the fatal end of the disease."
01/01/2000 - "Liver transplant is a new treatment for familial amyloidotic polyneuropathy. "
08/01/2013 - "The object of this study was to evaluate changes in peritransplant gastrointestinal symptoms and the nutritional status of familial amyloidotic polyneuropathy patients using the modified body mass index following a living-donor liver transplant. "
01/01/2000 - "The purpose of this phenomenological study is to describe the experience of waiting for a liver transplant from the familial amyloidotic polyneuropathy patients' perspective. "
08/01/2013 - "Although gastrointestinal symptoms were typically mild before living-donor liver transplant, the familial amyloidotic polyneuropathy group experienced a temporary deterioration in gastrointestinal symptoms after receiving the living-donor liver transplant but recovered after approximately 2 months. "